Literature DB >> 2275211

Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors.

A R Boobis1, D Sesardic, B P Murray, R J Edwards, A M Singleton, K J Rich, S Murray, R de la Torre, J Segura, O Pelkonen.   

Abstract

1. In the safety evaluation of drugs and other chemicals it is important to evaluate their possible inducing and inhibitory effects on the enzymes of drug metabolism. 2. While many similarities exist between species in their response to inducers and inhibitors, there are also important differences. Possible mechanisms of such variation are considered, with particular reference to the cytochrome P-450 system. 3. Differences in inhibition may be due to differences in inhibitory site of the enzyme involved, which is not always the active site of the enzyme, in competing pathways or in the pharmacokinetics of the inhibitor. 4. Differences in induction could be due to differences in the nature of the induction mechanism, in the isoenzyme induced, in tissue- or age-dependent regulation, in competing pathways for the substrate or its products, or in the pharmacokinetics of the inducing agent. 5. Examples of each of these possible differences are considered, often from our own work on the P450 IA subfamily, and results in animals are compared with those in humans, where possible. 6. At present, the differences between species in their response to inducers and inhibitors make extrapolation to humans from the results of animal studies difficult, so that ultimately such effects should be studied in the species of interest, humans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2275211     DOI: 10.3109/00498259009046835

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  14 in total

Review 1.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

2.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

Authors:  V A Eagling; J F Tjia; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

3.  The effect of furazolidone and furaltadone on drug metabolism in rats.

Authors:  B H Ali; M O Tanira; A K Bashir
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

4.  Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.

Authors:  Jacek Wójcikowski; Lydiane Pichard-Garcia; Patrick Maurel; Władysława A Daniel
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

5.  Effect of novel anti-inflammatory ethanolamine derivatives with antioxidant properties on drug metabolising enzymes.

Authors:  I Andreadou; E A Rekka; P N Kourounakis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

Review 6.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

Review 7.  The role of CYP enzymes in cocaine-induced liver damage.

Authors:  M Pasanen; P Pellinen; F Stenbäck; R O Juvonen; H Raunio; O Pelkonen
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

8.  Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.

Authors:  Mahnaz Salsali; Andrew Holt; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

Review 9.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Effect of tacrine hydrochloride on hepatic drug metabolism.

Authors:  T C Danbury; M Eccles; J Ford; C J Roberts
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.